Daiichi Sankyo targets $15 billion in oncology sales by 2030 as it expands ADC franchise

Daiichi Sankyo released a new five‑year business plan that sets a goal of nearly $15 billion in oncology revenue by 2030. The target is part of a broader ambition to push total company sales past 3 trillion Japanese yen, roughly $19 billion, within the same period.

The plan places a strong emphasis on the company's antibody‑drug conjugate (ADC) franchise, which it sees as the main driver of future growth in the oncology space. By expanding its ADC pipeline and advancing existing candidates, Daiichi aims to capture a larger share of the rapidly expanding market for targeted cancer therapies.

If achieved, the sales goal would position Daiichi among the leading global players in oncology and could attract significant investor interest. The outlook reflects the industry's shift toward precision medicines and highlights the company's confidence in its R&D capabilities.

Analysts will be watching how the ADC strategy unfolds, as execution risk remains a key factor in determining whether the ambitious revenue target can be realized.